

S4 Table. Fold increase of post-vaccination GMTs, stratified by chemotherapeutic regimen

| Serotype | Arm A (n=16) | | Arm B (n=9) | | p-value |
|--|---------------------------------|--------------|---------------------------------|--------------|---------|
| | Geometric mean fold increase | 95% CI | Geometric mean fold increase | 95% CI | |
| Fluoropyrimidine (n=25) | | | | | |
| 5 | 129.53 | 43.11-389.17 | 26.17 | 4.29-159.64 | 0.109 |
| 6B | 27.18 | 4.72-156.66 | 8.85 | 1.31-59.58 | 0.347 |
| 18C | 43.42 | 11.10-169.80 | 20.32 | 3.75-109.93 | 0.444 |
| 19A | 15.74 | 6.38-38.85 | 7.72 | 2.22-26.84 | 0.314 |
| Arm A (n=27) | | | Arm B (n=35) | | |
| Fluoropyrimidine+Oxaliplatin (n=62) | | | | | |
| 5 | 51.00 | 20.18-128.90 | 121.23 | 63.75-230.53 | 0.111 |
| 6B | 12.98 | 4.27-39.52 | 25.92 | 11.36-59.17 | 0.301 |
| 18C | 42.33 | 14.93-120.01 | 59.25 | 28.28-124.15 | 0.582 |
| 19A | 18.49 | 8.63-39.58 | 29.70 | 15.37-57.39 | 0.339 |

Fold increase in GMTs after vaccination in the two study arms, stratified by chemotherapeutic regimen.